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Although synthetic small interfering RNA (siRNA) has been extensively used to downregulate any 
protein-coding mRNA, several key issues still remain unsolved. The acyclic threoninol nucleic acid (aTNA), 
placed at certain siRNA positions, is a useful modification to reduce the oligonucleotides vulnerability towards 
nucleases. In addition, it can be exploited to avoid several OFF-target effects that limit the biological safety of the 
RNAi-based agents. 
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In attempt to control gene expression, synthetic 
oligonucleotide derivatives have been found to be appealing 
agents with improved therapeutic potential [1]. Antisense, 
siRNA and aptamers are well-established strategies to 
downregulate the expression of candidate genes. For example, 
siRNA-mediated silencing, taking advantages of the RNAi 
pathway and its protein complex (RISC), is a robust and 
potent strategy to trigger Post Transcriptional Gene Silencing 
(PTGS) [2]. Hence, siRNA-based therapeutics have attracted 
the attention as promising strategy for clinical purposes [3]. 
Recent therapeutic attempts have demonstrated the efficacy 
of the intravenous administration of siRNA molecules 
against cancer progression and metastasis [4]. SiRNA 
molecules consist of two strands: the antisense and the sense, 
being the antisense or guide strand selected and loaded into 
the RISC complex. The complementarity between the 
antisense strand and a specific mRNA guides the efficient 
degradation of the specific mRNA, decreasing the amount of 
the corresponding protein [5]. But despite the immense 
potential, siRNA technology has several disadvantages. 
Unmodified oligonucleotides are prompt degraded by 
bloodstream and cellular endo-/exo-nucleases. In addition, 
the polyanionic character of both cell membranes and nucleic 
acids makes problematic the cellular uptake. Finally 
OFF-target effects such as saturation of RNAi machinery, 
misloading of the passenger strand and activation of the 
interferon response limit the biological safety of 
siRNA-based therapeutics. Most of these disadvantages may 
be solved by using modified nucleic acids [6].  
Few years ago we reported that a modified siRNA was 
clearly better than the corresponding unmodified siRNA in a 
mouse model of inflammatory bowel disease (IBD) [7]. This 
modified siRNA was protected with a propanediol molecule 
at the 3’ termini and two residues of 2’-methylated-RNA at 
the other end of the sense strand (5’). The large increase on 
efficacy and the relatively simplicity of the modifications 
triggered our interest in modified siRNA with enhanced 
stability toward nucleases. Thus, we introduced several 
hydrophobic groups in the 3’-termini of siRNAs. These 
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modifications were designed to protect oligonucleotides 
toward nuclease degradation and fit into the hydrophobic 
pocket of RISC increasing the binding affinity of siRNA 
strands for RISC [8]. We observed that the smaller group in 
the antisense strand the more silencing of the corresponding 
siRNA. On the contrary the same modification in the 
3’-termini of the sense strand did not provide any substantial 
variation of the silencing activity. These interesting 
conclusions inspire us to design other new modifications for 
siRNA derivatives. 
For example, the N-N coupled nucleosides represent a new 
step in the development of novel nuclease resistant siRNAs 
[9]. The connection between two nucleosides occurs through 
the bases and not through the conventional phosphodiester 
linkage. Computational analysis of Klenow’s active site 
complexed with the N-N coupled nucleosides has revealed 
that the extreme resistance towards nucleases depends 
essentially on the lack of the scissile phosphate [9]. 
Another structural parameter to take into account is the 
pucker of the ribose. In double-helical B-DNA, the pucker of 
the furanose is “South” (S). But double-helical DNA in 
A-conformation and RNA are characterized by the “North” 
(N) pucker of N-type conformation. Several authors 
concentrate their research efforts in the preparation of siRNA 
carrying nucleosides that stabilize the North conformation. 
Among them, the locked nucleic acids (LNA) [10], the 
arabino nucleic acids (ANA) [11] and the 2’-fluoroarabino 
(FANA) have disclosed interesting properties for further 
applications [12]. We have investigated the effects of the 
N-type carbocyclic pseudo-nucleoside derivatives on RNA 
interference experiments [13]. Some pseudo-nucleoside 
modifications at both siRNA strands have disclosed 
enhanced resistance to degradation; furthermore the 
inhibitory properties of siRNA duplexes remained 
substantially unchanged. 
Recently, new paths have been beaten, instead of using 
“constrained” modifications able to preserve the A-form of 
RNA duplexes, more flexible acyclic derivatives have been 
Figure 1. Beneficial effects of the substitution of natural nucleobases by L-threoninol derivatives in siRNAs. Adapted from 
references [15, 17].  
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successfully used [14-16], to improve the stability towards 
nucleases and some biological properties. Specifically, we 
explored the effects of the acyclic L-threoninol backbone on 
the biological properties of siRNAs. The introduction of 2 
units L-threoninol modification at the 3’-protuding ends of 
siRNAs confers stronger nuclease resistance, less activation 
of the interferon response and greater potency respect to 
unmodified siRNA molecules [15] (Figure 1 upper right 
corner, lower left corner and central lower part, 
respectively). The promising results encourage us to further 
analyse the L-threoninol backbone inside the siRNA duplex 
[17]. Because the L-threoninol-thymine showed high 
destabilization potential at internal position of duplex RNA 
(ΔTm ≈ 10 ºC respect to native one), we thought to 
investigate how central modifications could affect the 
potency, for example helping the unwinding or hindering the 
proper activity of the slicer Ago2. We placed L-threoninol on 
positions crucial for the cleavage of the target mRNA: 10 and 
11 of the antisense strand. In case of modification on position 
10 the potency was strongly reduced (≈ 10-fold), on the other 
hand the modification of 11th position led to a slight decrease 
of potency respect to unmodified siRNAs (Figure 1 upper 
left corner). Hence, depending on position, L-threoninol 
modification interferes with correct and catalytically 
competent conformation of the Ago2 active site. 
Besides improved biological properties such as the 
resistance towards nucleases and sustained potency; we 
concentrate our efforts in the reduction of the OFF-target 
effects. One important source of these OFF-target effects 
comes from the wrong selection of the strand by RISC. Ratio 
between antisense and sense target activity can be assessed 
employing PsiCHECK2 reporter. Measuring the targeting 
ability of each strand independently, it provided rapid and 
reliable estimation on the efficiencies of siRNA-mediated 
inhibition for both the antisense (AS) and sense strand (SS). 
First, we examined whether L-threoninol modification at 
central positions, may induce a strong bias toward the correct 
guide-mediated silencing. Again, depending on position and 
also the mismatches type facing the L-threoninol unit, the 
ratio between AS and SS silencing is poor or increased. 
Finally, we thought to introduce of L-threoninol modification 
at the 2nd position of the 5’-termini of the passenger strand 
(Figure 1 lower right corner). The position 2 is important for 
the initial recognition of the loaded strand with the 
complementary mRNA. Disrupting or hampering the initial 
base pairing interactions could induce an inefficient 
assembly of the RISC complex and so the flawed processing 
of the mRNA complementary to the sense strand. The 
presence of single L-threoninol entailed complete abrogation 
of the passenger-mediated silencing without affecting the 
guide-mediated silencing. 
In conclusion, minimal, cost-effective L-threoninol 
modification, disclosing strong impact on potency, nucleases 
resistance, interferon response and unwanted 
passenger-mediated silencing, paves the way to valuable 
strategy in the tailored design of therapeutic siRNAs. 
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